Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Sign Up to like & getrecommendations! Published in 2024 at "Nature Medicine"
DOI: 10.1038/s41591-024-02824-y
Abstract: Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm,… read more here.
Keywords: phase renobate; unresectable hepatocellular; hepatocellular carcinoma; regorafenib ... See more keywords